Drug Profile


Alternative Names: AB-1010; Masican; Masipro; Masitinib mesilate; Masitinib mesylate; Masiviera

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AB Science
  • Class Antiasthmatics; Antineoplastics; Antirheumatics; Benzamides; Nootropics; Piperazines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Colony stimulating factor inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mastocytosis; Pancreatic cancer; Gastrointestinal stromal tumours; Amyotrophic lateral sclerosis; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Amyotrophic lateral sclerosis; Mastocytosis
  • Phase III Alzheimer's disease; Asthma; Colorectal cancer; Gastrointestinal stromal tumours; Malignant melanoma; Multiple myeloma; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer
  • Phase II/III Crohn's disease; Multiple sclerosis; Ovarian cancer; Progressive supranuclear palsy
  • Phase II Breast cancer; Chronic obstructive pulmonary disease; Head and neck cancer; Mood disorders; Non-small cell lung cancer; Parkinson's disease
  • Phase I/II Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Oesophageal cancer
  • Preclinical Stroke
  • No development reported Psoriasis
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 19 Oct 2017 Preclinical data in Amyotrophic lateral sclerosis released by AB Science
  • 15 Sep 2017 Committee for Medicinal Products for Human Use (CHMP) recommends the refusal of the marketing authorisation for masitinib for Mastocytosis in European Union as the benefits of anamorelin do not outweigh the potential risks
  • 31 Aug 2017 Updated efficacy data from a phase II/III trial in Amyotrophic lateral sclerosis released by AB Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top